Global Advanced Renal Cell Carcinoma Therapeutics Market Research Report 2023

Advanced renal cell carcinoma is associated with a type of kidney cancer that appears in the covering of the proximal complex tubule. The convoluted tubule is a very small part of tubes in the kidney that helps in transportation of unwanted particles from the blood to the urine. Advanced renal cell carcinoma is the most common type of kidney cancer in adults that represents nearly 2-3% of all cancer cases in adults. The disorder is asymptomatic in advanced renal cell carcinoma at initial stages that results with people often in the advanced stages of the disease by the time it is discovered. The initial symptoms of renal cell carcinoma are a general feeling of being unwell, hypertension, flank pain, weight loss, fever, blood in the urine, night sweats, and a mass in the abdomen. Management of renal cell carcinoma has seen significant development in the past few years, and new approaches are being established. Advanced renal cell carcinoma is a disease that normally cannot be treated by general therapy and is challenging to treat. Surgical removal of one or both kidneys should be considered in patients who suffer from metastatic disease before systemic therapy.

The global Advanced Renal Cell Carcinoma Therapeutics market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

Increase in aging population is one of the major factors driving the revenue growth of the renal cell carcinoma market. Furthermore, renal cell carcinoma is a rare disease with a small patient-base constitutingall ages from infants to older adults.  However, the disease is predominantly noted in age group of ~ 60-70 years, exposing a higher probability of occurrence. Expanding research into orphan drugs is a factor projected to create lucrative revenue potential for drug makers of renal cell carcinoma.

This report aims to provide a comprehensive presentation of the global market for Advanced Renal Cell Carcinoma Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Advanced Renal Cell Carcinoma Therapeutics.

The Advanced Renal Cell Carcinoma Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Advanced Renal Cell Carcinoma Therapeutics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Advanced Renal Cell Carcinoma Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Advanced Renal Cell Carcinoma Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Radiation Therapy

1.2.3 Chemotherapy

1.2.4 Hormone Therapy

1.2.5 Investigational Therapy

1.3 Market by Application

1.3.1 Global Advanced Renal Cell Carcinoma Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospitals

1.3.3 Cancer Research Institutes

1.3.4 Ambulatory Surgical Centers

1.3.5 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Advanced Renal Cell Carcinoma Therapeutics Market Perspective (2018-2029)

2.2 Advanced Renal Cell Carcinoma Therapeutics Growth Trends by Region

2.2.1 Global Advanced Renal Cell Carcinoma Therapeutics Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Advanced Renal Cell Carcinoma Therapeutics Historic Market Size by Region (2018-2023)

2.2.3 Advanced Renal Cell Carcinoma Therapeutics Forecasted Market Size by Region (2024-2029)

2.3 Advanced Renal Cell Carcinoma Therapeutics Market Dynamics

2.3.1 Advanced Renal Cell Carcinoma Therapeutics Industry Trends

2.3.2 Advanced Renal Cell Carcinoma Therapeutics Market Drivers

2.3.3 Advanced Renal Cell Carcinoma Therapeutics Market Challenges

2.3.4 Advanced Renal Cell Carcinoma Therapeutics Market Restraints

3.1 Global Top Advanced Renal Cell Carcinoma Therapeutics Players by Revenue

3.1.1 Global Top Advanced Renal Cell Carcinoma Therapeutics Players by Revenue (2018-2023)

3.1.2 Global Advanced Renal Cell Carcinoma Therapeutics Revenue Market Share by Players (2018-2023)

3.2 Global Advanced Renal Cell Carcinoma Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Advanced Renal Cell Carcinoma Therapeutics Revenue

3.4 Global Advanced Renal Cell Carcinoma Therapeutics Market Concentration Ratio

3.4.1 Global Advanced Renal Cell Carcinoma Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Advanced Renal Cell Carcinoma Therapeutics Revenue in 2022

3.5 Advanced Renal Cell Carcinoma Therapeutics Key Players Head office and Area Served

3.6 Key Players Advanced Renal Cell Carcinoma Therapeutics Product Solution and Service

3.7 Date of Enter into Advanced Renal Cell Carcinoma Therapeutics Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Advanced Renal Cell Carcinoma Therapeutics Historic Market Size by Type (2018-2023)

4.2 Global Advanced Renal Cell Carcinoma Therapeutics Forecasted Market Size by Type (2024-2029)

5.1 Global Advanced Renal Cell Carcinoma Therapeutics Historic Market Size by Application (2018-2023)

5.2 Global Advanced Renal Cell Carcinoma Therapeutics Forecasted Market Size by Application (2024-2029)

6.1 North America Advanced Renal Cell Carcinoma Therapeutics Market Size (2018-2029)

6.2 North America Advanced Renal Cell Carcinoma Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Advanced Renal Cell Carcinoma Therapeutics Market Size by Country (2018-2023)

6.4 North America Advanced Renal Cell Carcinoma Therapeutics Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Advanced Renal Cell Carcinoma Therapeutics Market Size (2018-2029)

7.2 Europe Advanced Renal Cell Carcinoma Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Advanced Renal Cell Carcinoma Therapeutics Market Size by Country (2018-2023)

7.4 Europe Advanced Renal Cell Carcinoma Therapeutics Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Advanced Renal Cell Carcinoma Therapeutics Market Size (2018-2029)

8.2 Asia-Pacific Advanced Renal Cell Carcinoma Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Advanced Renal Cell Carcinoma Therapeutics Market Size by Region (2018-2023)

8.4 Asia-Pacific Advanced Renal Cell Carcinoma Therapeutics Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Advanced Renal Cell Carcinoma Therapeutics Market Size (2018-2029)

9.2 Latin America Advanced Renal Cell Carcinoma Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Advanced Renal Cell Carcinoma Therapeutics Market Size by Country (2018-2023)

9.4 Latin America Advanced Renal Cell Carcinoma Therapeutics Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Advanced Renal Cell Carcinoma Therapeutics Market Size (2018-2029)

10.2 Middle East & Africa Advanced Renal Cell Carcinoma Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Advanced Renal Cell Carcinoma Therapeutics Market Size by Country (2018-2023)

10.4 Middle East & Africa Advanced Renal Cell Carcinoma Therapeutics Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 Acceleron Pharma

11.1.1 Acceleron Pharma Company Detail

11.1.2 Acceleron Pharma Business Overview

11.1.3 Acceleron Pharma Advanced Renal Cell Carcinoma Therapeutics Introduction

11.1.4 Acceleron Pharma Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

11.1.5 Acceleron Pharma Recent Development

11.2 Argos Therapeutics

11.2.1 Argos Therapeutics Company Detail

11.2.2 Argos Therapeutics Business Overview

11.2.3 Argos Therapeutics Advanced Renal Cell Carcinoma Therapeutics Introduction

11.2.4 Argos Therapeutics Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

11.2.5 Argos Therapeutics Recent Development

11.3 AVEO Pharmaceuticals

11.3.1 AVEO Pharmaceuticals Company Detail

11.3.2 AVEO Pharmaceuticals Business Overview

11.3.3 AVEO Pharmaceuticals Advanced Renal Cell Carcinoma Therapeutics Introduction

11.3.4 AVEO Pharmaceuticals Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

11.3.5 AVEO Pharmaceuticals Recent Development

11.4 Bayer

11.4.1 Bayer Company Detail

11.4.2 Bayer Business Overview

11.4.3 Bayer Advanced Renal Cell Carcinoma Therapeutics Introduction

11.4.4 Bayer Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

11.4.5 Bayer Recent Development

11.5 Bristol-Myers Squibb Company

11.5.1 Bristol-Myers Squibb Company Company Detail

11.5.2 Bristol-Myers Squibb Company Business Overview

11.5.3 Bristol-Myers Squibb Company Advanced Renal Cell Carcinoma Therapeutics Introduction

11.5.4 Bristol-Myers Squibb Company Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

11.5.5 Bristol-Myers Squibb Company Recent Development

11.6 Eisai

11.6.1 Eisai Company Detail

11.6.2 Eisai Business Overview

11.6.3 Eisai Advanced Renal Cell Carcinoma Therapeutics Introduction

11.6.4 Eisai Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

11.6.5 Eisai Recent Development

11.7 Exelixi

11.7.1 Exelixi Company Detail

11.7.2 Exelixi Business Overview

11.7.3 Exelixi Advanced Renal Cell Carcinoma Therapeutics Introduction

11.7.4 Exelixi Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

11.7.5 Exelixi Recent Development

11.8 Genentech

11.8.1 Genentech Company Detail

11.8.2 Genentech Business Overview

11.8.3 Genentech Advanced Renal Cell Carcinoma Therapeutics Introduction

11.8.4 Genentech Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

11.8.5 Genentech Recent Development

11.9 Immatics Biotechnologies

11.9.1 Immatics Biotechnologies Company Detail

11.9.2 Immatics Biotechnologies Business Overview

11.9.3 Immatics Biotechnologies Advanced Renal Cell Carcinoma Therapeutics Introduction

11.9.4 Immatics Biotechnologies Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

11.9.5 Immatics Biotechnologies Recent Development

11.10 Merck

11.10.1 Merck Company Detail

11.10.2 Merck Business Overview

11.10.3 Merck Advanced Renal Cell Carcinoma Therapeutics Introduction

11.10.4 Merck Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

11.10.5 Merck Recent Development

11.11 Novartis

11.11.1 Novartis Company Detail

11.11.2 Novartis Business Overview

11.11.3 Novartis Advanced Renal Cell Carcinoma Therapeutics Introduction

11.11.4 Novartis Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

11.11.5 Novartis Recent Development

11.12 Ono Pharmaceutical

11.12.1 Ono Pharmaceutical Company Detail

11.12.2 Ono Pharmaceutical Business Overview

11.12.3 Ono Pharmaceutical Advanced Renal Cell Carcinoma Therapeutics Introduction

11.12.4 Ono Pharmaceutical Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

11.12.5 Ono Pharmaceutical Recent Development

11.13 Pfizer

11.13.1 Pfizer Company Detail

11.13.2 Pfizer Business Overview

11.13.3 Pfizer Advanced Renal Cell Carcinoma Therapeutics Introduction

11.13.4 Pfizer Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

11.13.5 Pfizer Recent Development

11.14 Rexahn Pharmaceuticals

11.14.1 Rexahn Pharmaceuticals Company Detail

11.14.2 Rexahn Pharmaceuticals Business Overview

11.14.3 Rexahn Pharmaceuticals Advanced Renal Cell Carcinoma Therapeutics Introduction

11.14.4 Rexahn Pharmaceuticals Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

11.14.5 Rexahn Pharmaceuticals Recent Development

11.15 Hoffmann-La Roche

11.15.1 Hoffmann-La Roche Company Detail

11.15.2 Hoffmann-La Roche Business Overview

11.15.3 Hoffmann-La Roche Advanced Renal Cell Carcinoma Therapeutics Introduction

11.15.4 Hoffmann-La Roche Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

11.15.5 Hoffmann-La Roche Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Advanced Renal Cell Carcinoma Therapeutics Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of Radiation Therapy

    Table 3. Key Players of Chemotherapy

    Table 4. Key Players of Hormone Therapy

    Table 5. Key Players of Investigational Therapy

    Table 6. Global Advanced Renal Cell Carcinoma Therapeutics Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 7. Global Advanced Renal Cell Carcinoma Therapeutics Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 8. Global Advanced Renal Cell Carcinoma Therapeutics Market Size by Region (2018-2023) & (US$ Million)

    Table 9. Global Advanced Renal Cell Carcinoma Therapeutics Market Share by Region (2018-2023)

    Table 10. Global Advanced Renal Cell Carcinoma Therapeutics Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 11. Global Advanced Renal Cell Carcinoma Therapeutics Market Share by Region (2024-2029)

    Table 12. Advanced Renal Cell Carcinoma Therapeutics Market Trends

    Table 13. Advanced Renal Cell Carcinoma Therapeutics Market Drivers

    Table 14. Advanced Renal Cell Carcinoma Therapeutics Market Challenges

    Table 15. Advanced Renal Cell Carcinoma Therapeutics Market Restraints

    Table 16. Global Advanced Renal Cell Carcinoma Therapeutics Revenue by Players (2018-2023) & (US$ Million)

    Table 17. Global Advanced Renal Cell Carcinoma Therapeutics Market Share by Players (2018-2023)

    Table 18. Global Top Advanced Renal Cell Carcinoma Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Advanced Renal Cell Carcinoma Therapeutics as of 2022)

    Table 19. Ranking of Global Top Advanced Renal Cell Carcinoma Therapeutics Companies by Revenue (US$ Million) in 2022

    Table 20. Global 5 Largest Players Market Share by Advanced Renal Cell Carcinoma Therapeutics Revenue (CR5 and HHI) & (2018-2023)

    Table 21. Key Players Headquarters and Area Served

    Table 22. Key Players Advanced Renal Cell Carcinoma Therapeutics Product Solution and Service

    Table 23. Date of Enter into Advanced Renal Cell Carcinoma Therapeutics Market

    Table 24. Mergers & Acquisitions, Expansion Plans

    Table 25. Global Advanced Renal Cell Carcinoma Therapeutics Market Size by Type (2018-2023) & (US$ Million)

    Table 26. Global Advanced Renal Cell Carcinoma Therapeutics Revenue Market Share by Type (2018-2023)

    Table 27. Global Advanced Renal Cell Carcinoma Therapeutics Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 28. Global Advanced Renal Cell Carcinoma Therapeutics Revenue Market Share by Type (2024-2029)

    Table 29. Global Advanced Renal Cell Carcinoma Therapeutics Market Size by Application (2018-2023) & (US$ Million)

    Table 30. Global Advanced Renal Cell Carcinoma Therapeutics Revenue Market Share by Application (2018-2023)

    Table 31. Global Advanced Renal Cell Carcinoma Therapeutics Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 32. Global Advanced Renal Cell Carcinoma Therapeutics Revenue Market Share by Application (2024-2029)

    Table 33. North America Advanced Renal Cell Carcinoma Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 34. North America Advanced Renal Cell Carcinoma Therapeutics Market Size by Country (2018-2023) & (US$ Million)

    Table 35. North America Advanced Renal Cell Carcinoma Therapeutics Market Size by Country (2024-2029) & (US$ Million)

    Table 36. Europe Advanced Renal Cell Carcinoma Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 37. Europe Advanced Renal Cell Carcinoma Therapeutics Market Size by Country (2018-2023) & (US$ Million)

    Table 38. Europe Advanced Renal Cell Carcinoma Therapeutics Market Size by Country (2024-2029) & (US$ Million)

    Table 39. Asia-Pacific Advanced Renal Cell Carcinoma Therapeutics Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 40. Asia-Pacific Advanced Renal Cell Carcinoma Therapeutics Market Size by Region (2018-2023) & (US$ Million)

    Table 41. Asia-Pacific Advanced Renal Cell Carcinoma Therapeutics Market Size by Region (2024-2029) & (US$ Million)

    Table 42. Latin America Advanced Renal Cell Carcinoma Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 43. Latin America Advanced Renal Cell Carcinoma Therapeutics Market Size by Country (2018-2023) & (US$ Million)

    Table 44. Latin America Advanced Renal Cell Carcinoma Therapeutics Market Size by Country (2024-2029) & (US$ Million)

    Table 45. Middle East & Africa Advanced Renal Cell Carcinoma Therapeutics Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 46. Middle East & Africa Advanced Renal Cell Carcinoma Therapeutics Market Size by Country (2018-2023) & (US$ Million)

    Table 47. Middle East & Africa Advanced Renal Cell Carcinoma Therapeutics Market Size by Country (2024-2029) & (US$ Million)

    Table 48. Acceleron Pharma Company Detail

    Table 49. Acceleron Pharma Business Overview

    Table 50. Acceleron Pharma Advanced Renal Cell Carcinoma Therapeutics Product

    Table 51. Acceleron Pharma Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023) & (US$ Million)

    Table 52. Acceleron Pharma Recent Development

    Table 53. Argos Therapeutics Company Detail

    Table 54. Argos Therapeutics Business Overview

    Table 55. Argos Therapeutics Advanced Renal Cell Carcinoma Therapeutics Product

    Table 56. Argos Therapeutics Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023) & (US$ Million)

    Table 57. Argos Therapeutics Recent Development

    Table 58. AVEO Pharmaceuticals Company Detail

    Table 59. AVEO Pharmaceuticals Business Overview

    Table 60. AVEO Pharmaceuticals Advanced Renal Cell Carcinoma Therapeutics Product

    Table 61. AVEO Pharmaceuticals Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023) & (US$ Million)

    Table 62. AVEO Pharmaceuticals Recent Development

    Table 63. Bayer Company Detail

    Table 64. Bayer Business Overview

    Table 65. Bayer Advanced Renal Cell Carcinoma Therapeutics Product

    Table 66. Bayer Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023) & (US$ Million)

    Table 67. Bayer Recent Development

    Table 68. Bristol-Myers Squibb Company Company Detail

    Table 69. Bristol-Myers Squibb Company Business Overview

    Table 70. Bristol-Myers Squibb Company Advanced Renal Cell Carcinoma Therapeutics Product

    Table 71. Bristol-Myers Squibb Company Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023) & (US$ Million)

    Table 72. Bristol-Myers Squibb Company Recent Development

    Table 73. Eisai Company Detail

    Table 74. Eisai Business Overview

    Table 75. Eisai Advanced Renal Cell Carcinoma Therapeutics Product

    Table 76. Eisai Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023) & (US$ Million)

    Table 77. Eisai Recent Development

    Table 78. Exelixi Company Detail

    Table 79. Exelixi Business Overview

    Table 80. Exelixi Advanced Renal Cell Carcinoma Therapeutics Product

    Table 81. Exelixi Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023) & (US$ Million)

    Table 82. Exelixi Recent Development

    Table 83. Genentech Company Detail

    Table 84. Genentech Business Overview

    Table 85. Genentech Advanced Renal Cell Carcinoma Therapeutics Product

    Table 86. Genentech Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023) & (US$ Million)

    Table 87. Genentech Recent Development

    Table 88. Immatics Biotechnologies Company Detail

    Table 89. Immatics Biotechnologies Business Overview

    Table 90. Immatics Biotechnologies Advanced Renal Cell Carcinoma Therapeutics Product

    Table 91. Immatics Biotechnologies Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023) & (US$ Million)

    Table 92. Immatics Biotechnologies Recent Development

    Table 93. Merck Company Detail

    Table 94. Merck Business Overview

    Table 95. Merck Advanced Renal Cell Carcinoma Therapeutics Product

    Table 96. Merck Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023) & (US$ Million)

    Table 97. Merck Recent Development

    Table 98. Novartis Company Detail

    Table 99. Novartis Business Overview

    Table 100. Novartis Advanced Renal Cell Carcinoma Therapeutics Product

    Table 101. Novartis Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023) & (US$ Million)

    Table 102. Novartis Recent Development

    Table 103. Ono Pharmaceutical Company Detail

    Table 104. Ono Pharmaceutical Business Overview

    Table 105. Ono Pharmaceutical Advanced Renal Cell Carcinoma Therapeutics Product

    Table 106. Ono Pharmaceutical Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023) & (US$ Million)

    Table 107. Ono Pharmaceutical Recent Development

    Table 108. Pfizer Company Detail

    Table 109. Pfizer Business Overview

    Table 110. Pfizer Advanced Renal Cell Carcinoma Therapeutics Product

    Table 111. Pfizer Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023) & (US$ Million)

    Table 112. Pfizer Recent Development

    Table 113. Rexahn Pharmaceuticals Company Detail

    Table 114. Rexahn Pharmaceuticals Business Overview

    Table 115. Rexahn Pharmaceuticals Advanced Renal Cell Carcinoma Therapeutics Product

    Table 116. Rexahn Pharmaceuticals Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023) & (US$ Million)

    Table 117. Rexahn Pharmaceuticals Recent Development

    Table 118. Hoffmann-La Roche Company Detail

    Table 119. Hoffmann-La Roche Business Overview

    Table 120. Hoffmann-La Roche Advanced Renal Cell Carcinoma Therapeutics Product

    Table 121. Hoffmann-La Roche Revenue in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023) & (US$ Million)

    Table 122. Hoffmann-La Roche Recent Development

    Table 123. Research Programs/Design for This Report

    Table 124. Key Data Information from Secondary Sources

    Table 125. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Advanced Renal Cell Carcinoma Therapeutics Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Advanced Renal Cell Carcinoma Therapeutics Market Share by Type: 2022 VS 2029

    Figure 3. Radiation Therapy Features

    Figure 4. Chemotherapy Features

    Figure 5. Hormone Therapy Features

    Figure 6. Investigational Therapy Features

    Figure 7. Global Advanced Renal Cell Carcinoma Therapeutics Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 8. Global Advanced Renal Cell Carcinoma Therapeutics Market Share by Application: 2022 VS 2029

    Figure 9. Hospitals Case Studies

    Figure 10. Cancer Research Institutes Case Studies

    Figure 11. Ambulatory Surgical Centers Case Studies

    Figure 12. Others Case Studies

    Figure 13. Advanced Renal Cell Carcinoma Therapeutics Report Years Considered

    Figure 14. Global Advanced Renal Cell Carcinoma Therapeutics Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 15. Global Advanced Renal Cell Carcinoma Therapeutics Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 16. Global Advanced Renal Cell Carcinoma Therapeutics Market Share by Region: 2022 VS 2029

    Figure 17. Global Advanced Renal Cell Carcinoma Therapeutics Market Share by Players in 2022

    Figure 18. Global Top Advanced Renal Cell Carcinoma Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Advanced Renal Cell Carcinoma Therapeutics as of 2022)

    Figure 19. The Top 10 and 5 Players Market Share by Advanced Renal Cell Carcinoma Therapeutics Revenue in 2022

    Figure 20. North America Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 21. North America Advanced Renal Cell Carcinoma Therapeutics Market Share by Country (2018-2029)

    Figure 22. United States Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 23. Canada Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 24. Europe Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 25. Europe Advanced Renal Cell Carcinoma Therapeutics Market Share by Country (2018-2029)

    Figure 26. Germany Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. France Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 28. U.K. Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. Italy Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. Russia Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Nordic Countries Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. Asia-Pacific Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 33. Asia-Pacific Advanced Renal Cell Carcinoma Therapeutics Market Share by Region (2018-2029)

    Figure 34. China Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. Japan Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 36. South Korea Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. Southeast Asia Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. India Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Australia Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. Latin America Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 41. Latin America Advanced Renal Cell Carcinoma Therapeutics Market Share by Country (2018-2029)

    Figure 42. Mexico Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. Brazil Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 44. Middle East & Africa Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 45. Middle East & Africa Advanced Renal Cell Carcinoma Therapeutics Market Share by Country (2018-2029)

    Figure 46. Turkey Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 47. Saudi Arabia Advanced Renal Cell Carcinoma Therapeutics Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 48. Acceleron Pharma Revenue Growth Rate in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

    Figure 49. Argos Therapeutics Revenue Growth Rate in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

    Figure 50. AVEO Pharmaceuticals Revenue Growth Rate in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

    Figure 51. Bayer Revenue Growth Rate in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

    Figure 52. Bristol-Myers Squibb Company Revenue Growth Rate in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

    Figure 53. Eisai Revenue Growth Rate in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

    Figure 54. Exelixi Revenue Growth Rate in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

    Figure 55. Genentech Revenue Growth Rate in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

    Figure 56. Immatics Biotechnologies Revenue Growth Rate in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

    Figure 57. Merck Revenue Growth Rate in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

    Figure 58. Novartis Revenue Growth Rate in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

    Figure 59. Ono Pharmaceutical Revenue Growth Rate in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

    Figure 60. Pfizer Revenue Growth Rate in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

    Figure 61. Rexahn Pharmaceuticals Revenue Growth Rate in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

    Figure 62. Hoffmann-La Roche Revenue Growth Rate in Advanced Renal Cell Carcinoma Therapeutics Business (2018-2023)

    Figure 63. Bottom-up and Top-down Approaches for This Report

    Figure 64. Data Triangulation

    Figure 65. Key Executives Interviewed